gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PODDHealthcareSurgical Instruments

Insulet Corporation (PODD)

$165.02+6.56%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$154.86▼ 51.42% in range
Nov 3, 2025Low $130.47 · High $346.36Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Insulet closed at $165.02 on Nov 4, up 6.56%, 52.4% below its 52-week closing high. Volume of 2.6M shares was 1.89× its 20-day average (above normal).

Split-adjusted performance: +22.5% over one month, +9.1% over six months, -48.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $801.70M, up 23.5% from a year earlier, with a net margin of 11.8%.

Short interest was 5.6M shares at the Oct 15 settlement, up 5.1% from the prior report (8.1% of float, 3.1 days to cover).

Market cap$11.44B69.4M shares
Revenue · quarter$801.7M+23.5% YoY
Diluted EPS$1.37+328.1% YoY
P/E · TTM30.5×P/S 3.7×
Net margin11.8%Gross 70.2%
Dividend yieldNone
52-week range130.47 – 346.36−52.4% from high
Volume2.6M1.89× 20-day avg
Volatility · 60d33.8%Annualised
Short % of float8.1%3.1 days to cover
Net cash-$413.5MCash $534.9M
Next earnings—Not scheduled
Split-adjusted performance
1W +10.8%1M +22.5%3M +18.5%6M +9.1%YTD −41.9%1Y −48.2%3Y +26.2%5Y −44.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum62
Revenue growth82
Net margin84
Value (low P/E)50
Size88

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short5.6M+5.1% vs prior
Days to cover3.1Settled Oct 15
% of float8.1%
Short vol. 10d48.4%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PODDInsulet$165.02+6.56%+9.1%+23.5%11.8%30.5$11.44B
GMEDGLOBUS MEDICAL$87.10+9.45%−2.4%+5.9%19.2%21.8$11.69BCompare
PENPenumbra$322.45+0.76%−0.5%+15.6%10.3%80.9$12.71BCompare
BAXBaxter International$26.50+3.96%+56.1%+5.0%9.9%—$13.71BCompare
GKOSGlaukos$246.70+5.86%+82.4%+58.0%1.0%—$14.60BCompare
SOLVSolventum$89.35+5.42%+25.9%+2.2%4.2%10.6$15.21BCompare
TFXTeleflex Incorporated$149.87+7.09%+21.6%+28.9%17.5%—$6.35BCompare
HAEHaemonetics$127.42+5.94%+141.9%+5.6%9.7%60.2$5.80BCompare
MMSIMerit Medical Systems$90.63+7.69%+47.1%+8.4%10.2%33.9$5.43BCompare

News about Insulet

All news →
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research · Oct 28, 2026NeutralHere's Why Insulet (PODD) is a Strong Growth StockZacks Investment Research · Oct 16, 2026▲ PositiveIs it Prudent to Retain Insulet Stock in Your Portfolio for Now?Zacks Investment Research · Sep 8, 2026NeutralPODD DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Insulet Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 31 Deadline in Securities Class Action – PODDGlobeNewswire Inc. · Aug 29, 2026▼ NegativeBronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc. · Aug 27, 2026▼ Negative

Quick answers

What does Insulet do?
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage.
What is PODD's market cap?
$11.44B, based on the Nov 4 close of $165.02.
What is PODD's P/E ratio?
30.5× trailing-twelve-month earnings of $375.30M.
Does Insulet pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PODD is sold short?
5.6M shares, 8.1% of float, as of Oct 15, 2026.
What sector is PODD in?
Healthcare, in the Surgical Instruments industry.

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

HQ: Acton, MA5,400 employeesListed May 15, 2007insulet.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology